150 related articles for article (PubMed ID: 12060153)
21. [Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology].
Soepenberg O
Ned Tijdschr Geneeskd; 2000 Oct; 144(41):1979-80. PubMed ID: 11048563
[No Abstract] [Full Text] [Related]
22. Positron-emission tomography imaging in urological oncology: Current aspects and developments.
Rauscher I; Eiber M; Weber WA; Gschwend JE; Horn T; Maurer T
Int J Urol; 2018 Nov; 25(11):912-921. PubMed ID: 30103285
[TBL] [Abstract][Full Text] [Related]
23. [Clinical usefulness of FDG-PET in oncology].
Sasaki M
Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
[TBL] [Abstract][Full Text] [Related]
24. [Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology].
Comans EF; Hoekstra OS; Hoekman K; van der Hoeven JJ; Golding RP; Teule GJ
Ned Tijdschr Geneeskd; 2000 Aug; 144(32):1520-8. PubMed ID: 10949634
[TBL] [Abstract][Full Text] [Related]
25. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer.
Wong TZ; Jones EL; Coleman RE
Mol Imaging Biol; 2004; 6(1):55-62. PubMed ID: 15018829
[TBL] [Abstract][Full Text] [Related]
26. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology.
Vansteenkiste JF; Stroobants SG
Eur Respir J; 2001 Apr; 17(4):802-20. PubMed ID: 11401078
[TBL] [Abstract][Full Text] [Related]
27. Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002).
Bourguet P; Blanc-Vincent MP; Boneu A; Bosquet L; Chauffert B; Corone C; Courbon F; Devillers A; Foehrenbach H; Lumbroso JD; Mazselin P; Montravers F; Moretti JL; Talbot JN;
Br J Cancer; 2003 Aug; 89 Suppl 1(Suppl 1):S84-91. PubMed ID: 12915907
[No Abstract] [Full Text] [Related]
28. Value of FDG PET in the management of NSCLC.
Ukena D; Hellwig D
Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
[TBL] [Abstract][Full Text] [Related]
29. [Imaging of cancer using positron emission tomography].
Goldman S; Vanderhoeft A; Lebeau de Hemricourt E; Dusart M; Damhaut P; Wikler D
Rev Med Brux; 1999 Sep; 20(4):A365-8. PubMed ID: 10523925
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography as a diagnostic tool in oncology.
Schiepers C; Hoh CK
Eur Radiol; 1998; 8(8):1481-94. PubMed ID: 9853241
[TBL] [Abstract][Full Text] [Related]
31. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].
Hellwig D; Ukena D; Paulsen F; Bamberg M; Kirsch CM;
Pneumologie; 2001 Aug; 55(8):367-77. PubMed ID: 11505288
[TBL] [Abstract][Full Text] [Related]
32. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.
Lai CH; Huang KG; See LC; Yen TC; Tsai CS; Chang TC; Chou HH; Ng KK; Hsueh S; Hong JH
Cancer; 2004 Feb; 100(3):544-52. PubMed ID: 14745871
[TBL] [Abstract][Full Text] [Related]
33. [Positron emission tomography in oncology].
Hatazawa J; Higuchi I; Nakamura H
Gan To Kagaku Ryoho; 2003 Jun; 30(6):748-54. PubMed ID: 12852339
[TBL] [Abstract][Full Text] [Related]
34. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
35. Anatomolecular imaging with 2-deoxy-2-[18F]fluoro-D-glucose: bench to outpatient center.
Wahl RL
Mol Imaging Biol; 2003; 5(2):49-56. PubMed ID: 14499144
[TBL] [Abstract][Full Text] [Related]
36. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
Valk PE; Abella-Columna E; Haseman MK; Pounds TR; Tesar RD; Myers RW; Greiss HB; Hofer GA
Arch Surg; 1999 May; 134(5):503-11; discussion 511-3. PubMed ID: 10323422
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
38. Measurement of tumor response using [18F]-2-fluoro-2-deoxy-D-glucose and positron-emission tomography.
Lammertsma AA
J Clin Pharmacol; 2001 Jul; 41(S7):104S-106S. PubMed ID: 11452713
[No Abstract] [Full Text] [Related]
39. [Hybrid PET/CT in cancer imaging].
Seppänen M; Kajander S; Kemppainen J; Minn H
Duodecim; 2011; 127(11):1117-27. PubMed ID: 21755803
[TBL] [Abstract][Full Text] [Related]
40. Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: "systems molecular imaging" of glucose metabolism.
Shen B; Huang T; Sun Y; Jin Z; Li XF
Oncotarget; 2017 Jun; 8(26):43536-43542. PubMed ID: 28402949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
